The U.S. Food and Drug Administration (FDA) announced Thursday it approved a new drug that “can delay” the onset of stage 3 type 1 diabetes, which is the symptomatic stage of type 1 diabetes.
The drug, teplizumab-mzwv, is to be used to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older, who currently have stage 2 type 1 diabetes, the FDA announced.
Made by Provention Bio, in partnership with Sanofi, the new drug will be marketed in the United States under the brand name Tzield.
It is administered by intravenous infusion once daily for 14 consecutive days.
Tzield does not prevent or delay type 1 diabetes, which can appear at any age, but most commonly among children and young adults. This stage is not symptomatic….